Table 1 |
||||||
|
Percentage of patients achieving normalization1 of C-reactive protein levels and serum amyloid A protein levels |
||||||
|
Variable |
Canakinumab 10 mg N = 28 |
Canakinumab 25 mg N = 29 |
Canakinumab 50 mg N = 28 |
Canakinumab 90 mg N = 29 |
Canakinumab 150 mg N = 27 |
Triamcinolone acetonide 40 mg N = 56 |
|
|
||||||
|
CRP |
||||||
|
Baseline |
4 (14.3) |
8 (27.6) |
6 (21.4) |
6 (20.7) |
5 (18.5) |
12 (21.4) |
|
3 days post-dose |
6 (22.2) |
13 (46.4) |
9 (34.6) |
9 (32.1) |
11 (44.0) |
19 (35.8) |
|
7 days post-dose |
13 (46.4) |
21 (72.4)* |
16 (57.1) |
19 (67.9)* |
19 (70.4)* |
23 (41.8) |
|
4 weeks post-dose |
21 (77.8)* |
22 (78.6)* |
20 (74.1)* |
18 (64.3) |
20 (74.1)* |
27 (49.1) |
|
8 weeks post-dose |
17 (65.4)* |
21 (75.0)* |
17 (63.0) |
21 (75.0)* |
22 (81.5)* |
23 (42.6) |
|
|
||||||
|
SAA |
||||||
|
Baseline |
8 (28.6) |
9 (32.1) |
9 (32.1) |
8 (27.6) |
9 (33.3) |
23 (44.2) |
|
3 days post-dose |
15 (57.7) |
14 (50.0) |
16 (57.1) |
13 (46.4) |
13 (48.1) |
26 (48.1) |
|
7 days post-dose |
19 (67.9) |
22 (75.9)* |
19 (67.9) |
21 (75.0)* |
17 (65.4) |
25 (47.2) |
|
4 weeks post-dose |
24 (88.9)* |
24 (82.8) |
19 (70.4) |
20 (71.4) |
18 (69.2) |
34 (63.0) |
|
8 weeks post-dose |
18 (69.2) |
21 (80.8) |
18 (69.2) |
19 (70.4) |
20 (74.1) |
30 (57.7) |
|
|
||||||
|
*P < 0.05 vs triamcinolone acetonide 40 mg. 1Upper limit of normal: 3 mg/L for CRP, 6.7 mg/L for SAA. CRP, C-reactive protein; SAA, serum amyloid A protein. |
||||||
|
Schlesinger et al. Arthritis Research & Therapy 2011 13:R53 doi:10.1186/ar3297 |
||||||
